Remodeling p38 signaling in muscle controls locomotor activity via IL-15.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
16 Aug 2024
Historique:
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 14 8 2024
Statut: ppublish

Résumé

Skeletal muscle has gained recognition as an endocrine organ releasing myokines upon contraction during physical exercise. These myokines exert both local and pleiotropic health benefits, underscoring the crucial role of muscle function in countering obesity and contributing to the overall positive effects of exercise on health. Here, we found that exercise activates muscle p38γ, increasing locomotor activity through the secretion of interleukin-15 (IL-15). IL-15 signals in the motor cortex, stimulating locomotor activity. This activation of muscle p38γ, leading to an increase locomotor activity, plays a crucial role in reducing the risk of diabetes and liver steatosis, unveiling a vital muscle-brain communication pathway with profound clinical implications. The correlation between p38γ activation in human muscle during acute exercise and increased blood IL-15 levels highlights the potential therapeutic relevance of this pathway in treating obesity and metabolic diseases. These findings provide valuable insights into the molecular basis of exercise-induced myokine responses promoting physical activity.

Identifiants

pubmed: 39141732
doi: 10.1126/sciadv.adn5993
doi:

Substances chimiques

Interleukin-15 0
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadn5993

Auteurs

Cintia Folgueira (C)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Leticia Herrera-Melle (L)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Juan Antonio López (JA)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Victor Galvan-Alvarez (V)

Department of Physical Education, University of Las Palmas de Gran Canaria, Campus Universitario de Tafira s/n, Las Palmas de Gran Canaria 35017, Spain.
Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Canary Islands, Spain.

Marcos Martin-Rincon (M)

Department of Physical Education, University of Las Palmas de Gran Canaria, Campus Universitario de Tafira s/n, Las Palmas de Gran Canaria 35017, Spain.
Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Canary Islands, Spain.

María Isabel Cuartero (MI)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Unidad de Investigación Neurovascular, Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.

Alicia García-Culebras (A)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.

Phillip A Dumesic (PA)

Dana Farber Cancer Institute (DFCI), Department of Cell Biology, Harvard University Medical School, Boston, MA, USA.

Elena Rodríguez (E)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Luis Leiva-Vega (L)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Marta León (M)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Begoña Porteiro (B)

Department of Physiology, CiMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain.

Cristina Iglesias (C)

Department of Physiology, CiMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain.

Jorge L Torres (JL)

Complejo Asistencial de Zamora, Zamora, Spain.

Lourdes Hernández-Cosido (L)

Bariatric Surgery Unit, Department of General Surgery, University Hospital of Salamanca, Department of Surgery, University of Salamanca, Salamanca, Spain.

Clara Bonacasa (C)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Miguel Marcos (M)

Department of Internal Medicine, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Department of Medicine, University of Salamanca, Salamanca, Spain.

María Ángeles Moro (MÁ)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Jesús Vázquez (J)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Jose A L Calbet (JAL)

Department of Physical Education, University of Las Palmas de Gran Canaria, Campus Universitario de Tafira s/n, Las Palmas de Gran Canaria 35017, Spain.
Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Canary Islands, Spain.
Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.

Bruce M Spiegelman (BM)

Dana Farber Cancer Institute (DFCI), Department of Cell Biology, Harvard University Medical School, Boston, MA, USA.

Alfonso Mora (A)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Guadalupe Sabio (G)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH